Featured

Zymeworks targets $110 mln in Canada's first VC-backed IPO in two years

Zymeworks, a Vancouver biotherapeutics provider, has set the terms of its recently filed initial public offering in Canada and the United States. The event marks Canada’s first venture-backed IPO in two years. Zymeworks, backed by multiple VC and strategic investors, plans to raise as much as $110 million (US$82.8 million) from a sale of as many as 5.2 million common shares at US$13 to US$16 per unit, according to the updated prospectus. As a private company, Zymeworks has secured nearly US$150 million from investors, including the US$61.5 million raised in its Series A mezzanine financing last year.

Massachusetts bests New York as center for venture capital

Correlation looks at realized exit multiples and finds an increase

Europe no longer reliant on outside investors for late-stage funding

Fund performance: Column Group, Canaan lead emerging venture portfolio at UC

Dashboard: M&A, IPOs soar in March, thanks to unicorn exits

Weathergage’s Tim Bliamptis on distributions, micro VCs and emerging managers

Eniac raises $100 mln to handle larger seed rounds, launches full-service platform

OrbiMed’s Silverstein discloses Parkinson’s diagnosis, plans to stay in role

After legal dispute, Dallas firm changes name, adds partner